RUNX1-mutated acute myeloid leukemia (AML) defined by integrated morphologic, immunophenotypic, and molecular analyses.
Conditions
Interventions
More than 1 distinct RUNX1 mutations:None
Runt domain mutation:None
Outside-domain:None
ID domain mutation:None
AD domain mutation:None
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; 2. Treated at Nanfang Hospital, Southern Medical University after 2018; 3. Diagnosed with acute myeloid leukemia (AML) harboring RUNX1 mutations based on morphological, immunophenotypic, and molecular analyses (according to WHO 2022 criteria); 4. Meet the above inclusion criteria but died prior to the start of the study, provided they had regularly received outpatient follow-up or inpatient treatment and maintained complete medical records.
Exclusion criteria
Exclusion criteria: 1.Previous hematologic disorders; 2.Therapy-related acute myeloid leukemia or concomitant malignancies; 3.Patients deemed unsuitable for participation by the investigators;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival status from diagnosis to the last follow-up; | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of different types of RUNX1 mutations; | — |
Countries
China
Contacts
Public ContactJiang Ling
Southern Medical University Southern Hospital
Outcome results
None listed